Form 8-K - Current report:
SEC Accession No. 0001558370-25-011473
Filing Date
2025-08-14
Accepted
2025-08-14 07:35:34
Documents
13
Period of Report
2025-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xlo-20250814x8k.htm   iXBRL 8-K 52964
2 EX-99.1 xlo-20250814xex99d1.htm EX-99.1 154449
  Complete submission text file 0001558370-25-011473.txt   339169

Data Files

Seq Description Document Type Size
3 EX-101.SCH xlo-20250814.xsd EX-101.SCH 3441
4 EX-101.LAB xlo-20250814_lab.xml EX-101.LAB 16578
5 EX-101.PRE xlo-20250814_pre.xml EX-101.PRE 10708
15 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20250814x8k_htm.xml XML 5045
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 251214366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)